Future studies should explore more effective combinations of lifestyle interventions and pharmacotherapy, with emphasis on maintaining metabolic health and preserving lean mass, particularly through nutritional support and resistance training, among people at higher risk of sarcopenia
Wegovy, Ozempic and GLP1- inhibitors have arguably become the most popular medications in the modern world
and reports other support from Travere Therapeutics Inc, the Doris Duke Charitable Foundation, Bayer AG, AstraZeneca, Novo Nordisk, The George Institute for Global Health, CareDx and KBP BioSciences, and personal fees from Boehringer Ingelheim, Bayer Pharmaceuticals and Eli Lilly
doi: 10.1248/bpb.b21-01063 126